Immorta Bio, a Miami company that describes itself as working on treatments for aging, said on November 2, 2026 that the first person has received its experimental product, called SenoMune-02571. The company says the product is meant to help the immune system find and remove senescent cells, often nicknamed “zombie cells,” which it says build up with age and contribute to many age-related diseases1.
According to the company, the first patient was treated on October 29, 2026, in Mexico1. The person has advanced cancer and is taking part in a study run by independent doctors at Integrative Cancer Centers of America (ICCA)1. No results of any kind have been released.
What happened
The announcement is about a start, not an outcome. Immorta Bio says the study is “investigator-initiated,” meaning outside doctors designed and run it rather than the company itself1. The company says it developed and supplied the product, while the independent investigators conduct the study and manage patient care1.
SenoMune-0257 is described as a “proprietary nine-amino-acid peptide,” a short, lab-made chain of nine protein building blocks, designed to stimulate the immune system to recognize and eliminate senescent cells1. The company says it found and chose this peptide with help from artificial intelligence1.
Thomas Ichim, the company’s president and chief scientific officer, said in the announcement:
“To our knowledge, this represents the first human administration of an immunotherapy specifically designed to eliminate senescent cells. Unlike conventional small-molecule senolytics, our approach harnesses the immune system to target dysfunctional cells, potentially creating an entirely new class of therapeutics for diseases of aging.”1
“Senolytics” are drugs meant to kill senescent cells. Ichim’s point is that most such drugs are ordinary chemical compounds, while his company’s approach tries to get the body’s own immune defenses to do the job1. The “first” claim is the company’s own and is qualified with “to our knowledge.”
Why a cancer study for an aging treatment
Immorta Bio says it chose advanced cancer on purpose as the first setting to show that its approach can clear senescent cells, with the aim of later expanding to other diseases of aging1. The company lists a wide range of hoped-for uses, from brain, heart and metabolic disease to wound healing, organ failure and what it calls “systemic aging”1. These are goals, not findings.
The company has explained the cancer link before. In 2024, Ichim said that published research shows tumors surround themselves with senescent cells, and that more of these cells has been linked to worse survival and to resistance to chemotherapy, radiation and immunotherapy2. That reasoning comes from the company’s reading of other researchers’ work, not from a test of this product in people.
Gilberto Lopes, chief of medical oncology at the University of Miami, is quoted in the announcement. He is also a member of Immorta Bio’s Strategic Advisory Board1. He said advanced cancer “provides an important setting to investigate this innovative approach”1.
The evidence so far
Everything published about this product to date comes from the company. SenoMune-0257 builds on an earlier Immorta Bio product called SenoVax, which the company describes as a “multivalent cellular immunotherapy”1. On its website, the company described SenoVax as a vaccine made from dendritic cells, a type of immune cell that teaches other immune cells what to attack3.
The company has reported animal results for that earlier product. In June 2024, it said SenoVax led to the shrinking of established tumors in a lung cancer model, given without any other cancer treatment2. Those results were described in a patent filing, not a scientific paper2. In early 2025, the company said SenoVax caused tumors to shrink in animal models of lung, breast, brain (glioma) and pancreatic cancer3. The new announcement adds that related animal work showed activity in models of cancer, organ failure, diabetic wound healing, frailty and accelerated aging1.
The announcement lists two peer-reviewed papers, both in the Journal of Translational Medicine and both with Ichim as first author: one from 2025 titled “Reduction of Solid Tumors by Senescent Cell Immunization,” and one from 2026 titled “Synergistic senolytic-regenerative therapy significantly extends healthspan and lifespan”1. Biohack has not reviewed those papers for this article, and the announcement does not say whether either one tested SenoMune-0257 itself.
What it does not show yet
The company states plainly that SenoMune-0257 is investigational and that “its safety and efficacy in humans have not been established”1. A single person being treated tells readers nothing about whether the product is safe, whether it reaches senescent cells in the body, or whether it changes the course of cancer or any other disease.
Many basic details are missing from the announcement1:
- how many people the study plans to enroll;
- what dose is given, how, and how often;
- what the study is measuring, and how doctors will tell whether senescent cells were cleared;
- whether there is a comparison group;
- whether the study is listed in a public trial registry;
- when any results are expected.
There is also a gap between the earlier and current plans. In 2024 the company said it planned to file shortly with the US Food and Drug Administration (FDA) to begin treating people with advanced lung cancer2. The new announcement describes a study in Mexico and does not mention the FDA1. The sources do not say what happened with the earlier plan.
Finally, the animal results reported so far were for SenoVax, a cell-based product, while the product now given to a person is a short peptide1. The company calls the peptide an “evolution” of its earlier work1, but animal results for one product do not carry over automatically to another, and results in animals often do not hold up in people.
Who is behind it
Immorta Bio is led by Boris Reznik, its chairman and CEO, and Thomas Ichim, its co-founder, president and chief scientific officer1. Besides its work on senescent cells, the company is developing a second line of stem cell products it calls StemCellRevivify1. Its 2025 description says these include stem cell therapies made from iPSCs, cells reprogrammed in the lab to behave like early embryonic cells3.
The company’s public messaging is ambitious. Reznik said in the announcement: “We see this as a major step toward making the dream of dramatically longer, healthier human lives a medical reality”1. The company’s motto is “Treating Diseases of Aging and Treating Aging as Disease”1. Readers should weigh these statements as the hopes of the company that makes the product.
The company’s news page also lists recent business steps: selection in September 2026 for a life sciences cohort of NYU Stern’s Endless Frontier Labs, and the May 2026 appointment of Howard Brooks, a former Ernst & Young health sciences partner, to its board3. The sources do not say how the new study is funded or whether the investigators are paid by the company.
How it fits the field
Clearing senescent cells is one of the most discussed ideas in aging research, and most efforts so far have used chemical drugs, the “conventional small-molecule senolytics” Ichim contrasted his approach with1. Immorta Bio’s bet is that the immune system can be trained to do this work instead1. Whether that is safer, more effective, or neither is exactly what human studies would need to show.
What to watch next
- Whether the study appears in a public trial registry with its size, dose and goals.
- First safety reports from the independent investigators at ICCA.
- Any data showing the product changes senescent cell levels in patients, ideally published in a peer-reviewed journal.
- Whether the company files with the FDA or other regulators for studies outside Mexico.
- Whether the company moves, as it says it intends, from cancer into other diseases of aging1.
